Cardiol Therapeutics (TSE:CRDL) Shares Down 1.2% – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price was down 1.2% on Thursday. The company traded as low as C$1.61 and last traded at C$1.64. Approximately 133,566 shares changed hands during trading, a decline of 7% from the average daily volume of 143,722 shares. The stock had previously closed at C$1.66.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 5.55. The company has a market capitalization of C$193.21 million, a PE ratio of -4.68 and a beta of 0.36. The company’s 50-day simple moving average is C$2.39 and its 200-day simple moving average is C$1.97.

Cardiol Therapeutics (TSE:CRDL) last announced its earnings results on Wednesday, August 12th. The company reported C($0.05) EPS for the quarter. As a group, sell-side analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.